SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-025013
Filing Date
2023-07-20
Accepted
2023-07-20 11:45:36
Documents
18
Period of Report
2023-07-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 55462
2 ex4-1.htm EX-4.1 125003
3 ex4-2.htm EX-4.2 118332
4 ex4-3.htm EX-4.3 118606
5 ex10-1.htm EX-10.1 338936
6 ex99-1.htm EX-99.1 14964
  Complete submission text file 0001493152-23-025013.txt   1139467

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lixt-20230718.xsd EX-101.SCH 3785
8 XBRL DEFINITION FILE lixt-20230718_def.xml EX-101.DEF 26651
9 XBRL LABEL FILE lixt-20230718_lab.xml EX-101.LAB 36777
10 XBRL PRESENTATION FILE lixt-20230718_pre.xml EX-101.PRE 25275
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5200
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 231098723
SIC: 2834 Pharmaceutical Preparations